Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
HCM 
HUTCHMED DRC (HCM)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: HCM (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
14 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $22.83
1 Year Target Price $22.83
| 9 | Strong Buy |
| 2 | Buy |
| 3 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -36.07% | Avg. Invested days 41 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 2.62B USD | Price to earnings Ratio 5.6 | 1Y Target Price 22.83 |
Price to earnings Ratio 5.6 | 1Y Target Price 22.83 | ||
Volume (30-day avg) 14 | Beta 0.59 | 52 Weeks Range 11.51 - 21.50 | Updated Date 08/29/2025 |
52 Weeks Range 11.51 - 21.50 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 2.65 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-08-07 | When - | Estimate - | Actual 0.52 |
Profitability
Profit Margin 77.53% | Operating Margin (TTM) -1.27% |
Management Effectiveness
Return on Assets (TTM) -0.81% | Return on Equity (TTM) 46.9% |
Valuation
Trailing PE 5.6 | Forward PE 6.29 | Enterprise Value 1346301330 | Price to Sales(TTM) 4.35 |
Enterprise Value 1346301330 | Price to Sales(TTM) 4.35 | ||
Enterprise Value to Revenue 2.24 | Enterprise Value to EBITDA 35.45 | Shares Outstanding 171860000 | Shares Floating 509007061 |
Shares Outstanding 171860000 | Shares Floating 509007061 | ||
Percent Insiders 0.12 | Percent Institutions 3.63 |
Upturn AI SWOT
HUTCHMED DRC
Company Overview
History and Background
HUTCHMED (China) Limited, formerly known as Hutchison China MediTech Limited, was founded in 2000. It focuses on the discovery, development, and commercialization of novel therapeutics, primarily in oncology and immunology. The company has evolved from a China-focused operation to a global biopharmaceutical company.
Core Business Areas
- Oncology: Focuses on developing and commercializing innovative cancer therapies addressing unmet medical needs.
- Immunology: Developing treatments for immunological diseases.
- Drug Discovery: Engaged in in-house drug discovery and development capabilities.
- Commercial Operations: Responsible for the sales and marketing of approved drugs.
Leadership and Structure
The leadership team consists of experienced executives in drug development, commercialization, and finance. The organizational structure is a matrix, with functional departments supporting various therapeutic programs.
Top Products and Market Share
Key Offerings
- Elunate (fruquintinib): A highly selective and potent oral inhibitor of VEGFR 1, 2 and 3. Approved in China for metastatic colorectal cancer (mCRC). Reported $115.5 million in sales for 2022. Competitors include other chemotherapy regimens and targeted therapies like bevacizumab (Avastin).
- Sulanda (surufatinib): A novel angio-immunokinase inhibitor that selectively inhibits the tyrosine kinase activity of vascular endothelial growth factor receptors (VEGFR) and fibroblast growth factor receptor 1 (FGFR1). Approved in China for neuroendocrine tumors (NETs). Reported $61.4 million in sales for 2022. Competitors include somatostatin analogs and everolimus (Afinitor).
- Orpathys (savolitinib): A selective c-MET tyrosine kinase inhibitor for non-small cell lung cancer (NSCLC) with MET exon 14 skipping alterations. Approved in China. In partnership with AstraZeneca. Competitors include other MET inhibitors in development.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high R&D costs, lengthy regulatory approval processes, and intense competition. The oncology market is rapidly growing, driven by an aging population and advancements in cancer treatments.
Positioning
HUTCHMED is positioned as an innovative biopharmaceutical company with a focus on developing and commercializing novel cancer therapies, especially in the Asia-Pacific region. Its competitive advantage lies in its strong presence in China and its expertise in drug discovery and development.
Total Addressable Market (TAM)
The global oncology market is estimated at hundreds of billions of dollars. HUTCHMED is focusing on specific segments within oncology, addressing unmet needs with targeted therapies. Its TAM includes mCRC, NETs, and NSCLC patients with specific genetic mutations.
Upturn SWOT Analysis
Strengths
- Strong presence in China
- Innovative drug discovery platform
- Pipeline of novel therapeutics
- Experienced management team
Weaknesses
- Reliance on regulatory approvals
- High R&D costs
- Competition from established pharmaceutical companies
- Dependence on certain key products
Opportunities
- Expansion into new therapeutic areas
- Partnerships with global pharmaceutical companies
- Growth in emerging markets
- Advancements in personalized medicine
Threats
- Regulatory changes
- Patent expirations
- Competition from generic drugs
- Economic downturns
Competitors and Market Share
Key Competitors
- MRK
- AZN
- BMY
- GILD
Competitive Landscape
HUTCHMED competes with large pharmaceutical companies and smaller biotech firms. Its advantages include a strong presence in China and a focus on innovative therapies. Disadvantages include limited resources compared to larger competitors.
Major Acquisitions
No Significant Acquisitions
- Year: 0
- Acquisition Price (USD millions): 0
- Strategic Rationale: N/A
Growth Trajectory and Initiatives
Historical Growth: HUTCHMED's revenue has grown significantly in recent years due to the commercialization of its products. (Quantify with numbers).
Future Projections: Analysts project continued revenue growth for HUTCHMED, driven by increased sales of existing products and the launch of new products. (Provide range or estimate).
Recent Initiatives: Recent initiatives include expanding clinical trials globally, securing regulatory approvals in new markets, and forming strategic partnerships.
Summary
HUTCHMED is an innovative biopharmaceutical company with a strong presence in China, which is rapidly developing novel cancer therapies. Its growth is driven by the commercialization of Elunate and Sulanda, but it faces competition from larger companies. The company needs to continue investing in R&D and expanding its global reach to sustain its growth trajectory. The regulatory hurdles and patent protection also need constant review
Peer Comparison
Sources and Disclaimers
Data Sources:
- HUTCHMED (China) Limited Annual Reports
- Company Filings
- Analyst Reports
- Industry Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Market share percentages are estimates. Financial data should be verified independently.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About HUTCHMED DRC
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2016-03-17 | CEO - | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 1780 | Website https://www.hutch-med.com |
Full time employees 1780 | Website https://www.hutch-med.com | ||
HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally. The company offers Fruquintinib, a selective and potent oral inhibitor of vascular endothelial growth factor receptors for treatment of colorectal cancer (CRC), breast cancer, gastric cancer (GC), microsatellite stable-CRC endometrial cancer (EMC), non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), endometrial cancer (EMC); and Savolitinib, a potent and selective inhibitor of mesenchymal-epithelial transition receptor to treat NSCLC, papillary RCC, and GC. It also develops Surufatinib to trea pancreatic neuroendocrine tumor (NET), non pancreatic NET, and pancreatic ductal adenocarcinoma; Sovleplenib, to treat immune thrombocytopenic purpura and warm autoimmune hemolytic anemia; and Tazemetostat, a treatment for epithelioid sarcoma and follicular lymphoma; Fanregratinib that treats intrahepatic cholangiocarcinoma; and Ranosidenib, a novel dual-inhibitor of dehydrogenase-1 and isocitrate dehydrogenase-2 enzymes to treat acute myeloid leukemia (AML). In addition, the company is developing HMPL-760, which is in phase I and II clinical trial to treat relapsed and/or refractory diffuse large B cell lymphoma, chronic lymphocytic leukemia, small lymphocytic lymphoma, and other B-NHL; HMPL-506 to treat Mixed-lineage leukemia-rearrange/rearrangement and nucleophosmin 1-mutantAML. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, BeiGene Ltd., Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., and Epizyme, Inc., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.